Cloning, Overexpression, and Characterization of Glutaredoxin 2, An Atypical Glutaredoxin from Escherichia coli*

(Received for publication, January 24, 1997, and in revised form, February 19, 1997)

Alexios Vlamis-Gardikas Dagger , Fredrik Åslund Dagger , Giannis Spyrou Dagger §, Tomas Bergman and Arne Holmgren Dagger par

From the Dagger  Medical Nobel Institute for Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden and the  Laboratory of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Glutaredoxin 2 (Grx2) from Escherichia coli catalyzes GSH-disulfide oxidoreductions via two redox-active cysteine residues, but in contrast to glutaredoxin 1 (Grx1) and glutaredoxin 3 (Grx3), is not a hydrogen donor for ribonucleotide reductase. To characterize Grx2, a chromosomal fragment containing the E. coli Grx2 gene (grxB) was cloned and sequenced. grxB (645 base pairs) is located between the rimJ and pyrC genes while an open reading frame immediately upstream grxB encodes a novel transmembrane protein of 402 amino acids potentially belonging to class II of substrate export transporters. The deduced amino acid sequence for Grx2 comprises 215 residues with a molecular mass of 24.3 kDa. There is almost no similarity between the amino acid sequence of Grx2 and Grx1 or Grx3 (both 9-kDa proteins) with the exception of the active site which is identical in all three glutaredoxins (C9PYC12 for Grx2). Only limited similarities were noted to glutathione S-transferases (Grx2 amino acids 16-72), and protein disulfide isomerases from different organisms (Grx2 amino acids 70-180). Grx2 was overexpressed and purified to homogeneity and its activity was compared with those of Grx1 and Grx3 using GSH, NADPH, and glutathione reductase in the reduction of 0.7 mM beta -hydroxyethyl disulfide. The three glutaredoxins had similar apparent Km values for GSH (2-3 mM) but Grx2 had the highest apparent kcat (554 s-1). Expression of two truncated forms of Grx2 (1-114 and 1-133) which have predicted secondary structures similar to Grx1 (beta alpha beta alpha beta beta alpha ) gave rise to inclusion bodies. The mutant proteins were resolubilized and purified but lacked GSH-disulfide oxidoreductase activity. The latter should therefore require the participation of amino acid residues from the COOH-terminal half of the molecule and is probably not confined to a Grx1-like NH2-terminal subdomain. Grx2 being radically different from the presently known glutaredoxins in terms of molecular weight, amino acid sequence, catalytic activity, and lack of a consensus GSH-binding site is the first member of a novel class of glutaredoxins.


INTRODUCTION

Glutaredoxin (Grx)1 was discovered as a glutathione-dependent hydrogen donor for Escherichia coli ribonucleotide reductase (1-3). The first isolated glutaredoxin (glutaredoxin 1) (Grx1), is a 9-kDa protein with two catalytic cysteine residues in the sequence Cys-Pro-Tyr-Cys (4). Apart from its protein disulfide reductase activity with ribonucleotide reductase, Grx1 is also a general GSH-disulfide oxidoreductase, reducing disulfides like beta -hydroxyethyl disulfide (HED) in a coupled system with GSH, NADPH, and glutathione reductase (3, 5) (HED assay, Equations 1 and 2),
<UP>2GSH + </UP>X<UP>−S−S−</UP>X <LIM><OP><ARROW>→</ARROW></OP><UL><UP>Grx</UP></UL></LIM><UP> GSSG + 2</UP>X<UP>−SH</UP> (Eq. 1)
<UP>GSSG + NADPH + H<SUP>+</SUP> </UP><LIM><OP><ARROW>→</ARROW></OP><UL><UP>GR</UP></UL></LIM><UP> 2GSH + NADP<SUP>+</SUP></UP> (Eq. 2)
where X-S-S-X is HED and X-SH is beta -mercaptoethanol.

In a crude extract of wild-type E. coli B, Grx1 constitutes only about 2% of the total GSH-disulfide oxidoreductase activity (HED assay) (5, 6). Later work resulted in the isolation of two additional glutaredoxins which accounted for the major general GSH-disulfide oxidoreductase activity (6). From their order of elution on Sephadex G-50 the new glutaredoxins were called glutaredoxin 2 (Grx2) and glutaredoxin 3 (Grx3). NH2-terminal sequencing of Grx2 and Grx3 demonstrated that both enzymes contained the typical glutaredoxin motif (Cys-Pro-Tyr-Cys), although Grx2 had an atypical size (Mr 27,000) for glutaredoxin. Grx3 (9 kDa) with 82 residues showed 33% sequence identity and a similar secondary structure and tertiary fold (7) as the well characterized Grx1 (8, 9). Thus both Grx1 and Grx3 have the thioredoxin fold (10, 11) and are members of the thioredoxin (Trx) superfamily of disulfide oxidoreductases. In contrast to Grx3, which has about 5% of the catalytic activity of Grx1 as a disulfide reductant of ribonucleotide reductase, Grx2 lacks such activity (6). The relative abundance of Grx2 in E. coli (6) makes further investigations of the structure and function of this unknown protein necessary to understand the SH-metabolism in the cell. In this study we have cloned and sequenced the gene coding for Grx2 (grxB) and another gene located immediately upstream grxB coding for a potential transmembrane protein. Grx2 showed large differences to previously known glutaredoxins.


MATERIALS AND METHODS

beta -Hydroxyethyl disulfide (HED) was from Aldrich. NADPH and glutathione reductase (yeast) were from Sigma. Diaflo YM10 membranes were from Amicon. E. coli Grx1 and Grx3, Trx, and thioredoxin reductase were purified to homogeneity as described (12). Oligonucleotides were synthesized by Pharmacia Biotech Ltd. Restriction enzymes, T4 DNA ligase, and Taq polymerase were from Promega.

Bacterial Strains and Plasmids

XL-1 blue and DH5alpha were used for plasmid propagation and cloning purposes. Strain GI698 (13) was a gift Dr. J. McCoy (Genetics Institute, Boston, MA) and was used for overexpression of Grx2.

Measurement of Protein Concentration

Total protein was measured using the Bradford protein assay (14) adapted for use on microtiter plates. For pure Grx2, a molar extinction coefficient of 21,860 M-1·cm-1 at 280 nm was used.

Protein Preparation and Carboxymethylation

A nearly homogenous preparation (more than 90% pure as judged by SDS-PAGE) of E. coli Grx2 (5 nmol in 50 µl) purified as described (6), was reduced in 0.5 ml of 50 mM Tris-Cl, pH 8.0, by incubation for 4 h at 4 °C in the presence of 1 mM dithiothreitol. Carboxymethylation was performed by the addition of 300 µl of 6 M guanidine hydrochloride, 0.4 M Tris-Cl, pH 8.1, 2 mM EDTA, 5 mM neutralized 14C-iodoacetic acid (Amersham, approximately 2400 cpm/nmol), and incubation for 4 h at 4 °C. Reagents and contaminating proteins were removed by reverse-phase chromatography on a C4 (Vydac) HPLC column equilibrated in 0.1% trifluoroacetic acid in water and eluted with a linear gradient of acetonitrile (0-40% during 60 min, 1 ml/min) containing 0.1% trifluoroacetic acid.

Peptide Generation, Purification, Nomenclature, and Sequence Analysis

HPLC-purified 14C-carboxymethylated Grx2 was digested for 4 h at 37 °C with Lys-C endoprotease (Wako), at an enzyme to protein ratio of 1:10 in 0.1 M ammonium bicarbonate, pH 8.0, containing M guanidine hydrochloride. The resulting peptides (K peptides, Fig. 1) were purified by reverse-phase (C18) HPLC using conditions described above. Peptides (D peptides, Fig. 1) were generated also by cleavage with Asp-N endoprotease (Boehringer-Mannheim) and purified on a C4 HPLC column, see above. Amino acid sequence analysis of all peptides was performed using an Applied Biosystems 470A sequencer and phenylthiohydration detection was by reverse-phase HPLC in a Hewlett-Packard 1090 system (15).


Fig. 1. Nucleotide sequence of the grxB region including ORFbefgrxB, grxB, and their deduced amino acid sequences. The start and 5' to 3' direction for the translation of the rimJ and pyrC regions are indicated. Numbers to the left correspond to the nucleotide sequence and the numbers to the right refer to the amino acid sequence. The D and K proteolytic peptides derived from Grx2 are shown under the corresponding amino acid sequence of the protein. Boxed nucleotides upstream from grxB correspond to potential TTGACa-35 promoter consensus sequences.
[View Larger Version of this Image (58K GIF file)]


Construction of PCR Primers and Cloning of an 180-Base Pair PCR Product for Grx2

Two forward primers corresponding to the published NH2-terminal sequence of Grx2 (6) were synthesized and named N1 (amino acids 1-8: 5'-ATGAAACTGTACATCTA(C/T)GA(C/T)CA-3') and N2 (amino acids 10-15: 5'-CCGTACTGCCTGAA(A/G)GC-3'). The reverse primers were based on the peptide K8 (DDSRYMPESMDIVHYVDK) and were named C1 (amino acids 4-9 of K8: 5'-CATAGATTCCGGCAT(G/A)TA-3') and C2 (amino acids 9-16 of K8: 5'-TCAACGTAGTGAACGAT(G/A)TCCAT-3'). A 28-cycle PCR reaction (94 °C for 1 min, 46 °C for 1.2 min, 72 °C for 2 min) was run against a preparation of wild type (strain K12) DNA using all four combinations of primers. Amplified DNA using the N2/C1 and N2/C1 primers was subcloned into pGEM-T vector (Promega) and sequenced.

Screening the Kohara Phage Library and Isolation of Phage DNA

An 180-bp PCR product resulting from amplification using the N2 and C1 primers contained sequences corresponding to peptides from Grx2. The PCR product was labeled with 32P by random priming and used as a probe to screen a nitrocellulose filter containing DNA from the Kohara phage library (16). Phage clone 233 was selected and propagated in E. coli strain Y1090. lambda  Phage DNA was purified using the plate lysate method (17), with the modification of resuspending pelleted phage particles in lambda  diluent (instead of TE) after DNase I treatment. The modification resulted to higher yields of non-degraded phage DNA.

Construction of Recombinant Plasmids for Sequence Analysis and Overexpression

Phage DNA from clone 233 was digested with BamHI and EcoRI, separated on a 1% agarose gel, transferred to a nitrocellulose membrane, and finally probed using the 180-bp PCR fragment (N2 and C1 primers). A ~4.2-kilobase band which hybridized strongly with the probe was cloned into vector pGEM-3Z (Promega) and used for sequence analysis. The nucleotide sequence of the cloned fragment was determined using the Taq DyeDeoxy terminator cycle sequencing on an automated laser fluorescent DNA sequencer (A.L.F., Pharmacia) according to the protocol supplied by the manufacturer. Primers (fluorescent) were made initially based on the 180-bp PCR fragment, and later on the sequences revealed upstream and downstream. Sequencing stopped after the known pyrC and rimJ regions were reached.

Overexpression of Grx2

grxB was amplified using primers containing NdeI (G2-FNdeI primer: 5'-TGGAGGAGTCATATGAAGCTATAC-3') and BamHI (G2-RCBamHI primer: 5'-CGCGGCGGGGGATCCTTAAATCGC-3') sites at the 5' and 3' termini of the gene, respectively. The amplified fragment was then digested with NdeI and BamHI and was cloned into the pTRXFUS (13) vector replacing the Trx gene and giving rise the Grx2 expression vector named pe1Grx2. Strain GI698 transformed with pe1Grx2 was grown in 1-liter cultures at 30 °C. Grx2 expression was induced at an optical density of cells at 600 nm (A600) between 0.4 and 0.5 with a final concentration of 100 µg/ml DL-tryptophan. Cells were then grown for up to 16 h in an orbital shaker at 100 rpm and harvested by centrifugation at 6000 × g for 20 min.

Truncated forms of grxB were constructed using the G2-FNdeI primer and primers G2del1RC (for 1-114, 5'-GAAATATTTGCGGGATCCTTATTAAGAAAACTCATC-3') or G2del2RC (for 1-133, 5'-AGAGTGGGCCAGGGATCCTTAAAAATTACCCGCGC-3'). Both primers contained a BamHI site. The expression strategy for the truncated forms was identical to that used for the wild-type protein with the exception that temperatures of 20 and 25 °C also were used in separate experiments for growth and expression.

Purification of Recombinant Grx2

Cells, 6.2 g, were resuspended in 50 ml of 50 mM Tris-Cl, pH 8.0, and placed on ice. Lysozyme (0.5 mg/ml final), phenylmethylsulfonyl fluoride (1 mM final), and DNase I (50 µg/ml final) were added sequentially after 5 min each and the mixture was left on ice for 1 h. EDTA was added to a final concentration of 1 mM and the cell lysate was thoroughly sonicated (on ice three times at full power for 1 min). The supernatant was collected after centrifugation at 24,000 × g for 35 min at 4 °C and the pellet was washed with 10 ml of 100 mM Tris-Cl, pH 8.0, recentrifuged, and the new supernatant was pooled with the first. The pool was dialyzed overnight against 20 mM Tris base (pH above 10) and was applied to a 200-ml DE52 column (Whatman) equilibrated with the same buffer. Grx2 bound to the column and was eluted by 50 mM Tris-Cl, pH 8.0, in a volume of approximately 2 liters which after concentration through a tangential flow cartridge with a cut-off of 10 kDa (Prep/Scale-TFF cartridge, Millipore) was applied to a column (100 cm × 1.6 cm2) of Sephadex G-50 superfine (Pharmacia) with 100 mM potassium phosphate, pH 7.0, as equilibration and running buffer.

Preparation of Soluble Truncated Forms of Grx2

The 1-114 and 1-133 truncated forms of Grx2 were recovered from the insoluble fraction after cell lysis. The insoluble pellet from a 1-liter culture was washed in 20 ml of 100 mM Tris-Cl, pH 8.0, 1 mM EDTA, recentrifuged, and solubilized with 10 ml of 100 mM Tris-Cl, pH 8.0, 1 mM EDTA, 100 mM dithiothreitol, 8 M urea. The urea extract was diluted 100-fold by dropwise addition to 1 liter of 100 mM Tris-Cl, pH 8.0, 1 mM EDTA at 4 °C. The mixture was concentrated to 10 ml on a Diaflo membrane and centrifuged at 24,000 × g for 35 min at 4 °C. The supernatant contained the Grx2 1-114 or Grx2 1-133 fragment in soluble form. The purity of these preparations was more than 50% as judged by SDS-PAGE.

Determination of Glutaredoxin Activity (HED assay)

A fresh mixture of 1 mM GSH, 0.2 mM NADPH, 2 mM EDTA, 0.1 mg/ml bovine serum albumin, and 6 µg/ml yeast GR was prepared in 100 mM Tris-Cl, 2 mM EDTA, pH 8.0 (3). To 500 µl of this mixture in semimicro cuvettes, HED was added to a final concentration of 0.7 mM. After 3 min glutaredoxin was added to the sample cuvettes and the decrease in A340 was recorded the following 5 min using a Zeiss PMQ3 spectrophotometer. Activity was expressed as micromoles of NADPH oxidized per min using a molar extinction coefficient of 6200 M-1·cm-1. Steady-state kinetics measurements were performed in a final volume of 100 µl using a Molecular Devices Thermomax microplate reader. Values of Delta A340 were multiplied by a factor of 4.3 to give the Delta A340 of a cuvette with a path length of 1 cm. All activity measurements were made at 25 °C.

Determination of SH Groups

This was done spectrophotometrically with 1 mM 5,5'-dithiobis(2-nitrobenzoic acid) in 200 mM Tris-Cl, pH 8.0, 6 M guanidine hydrochloride, using a molar extinction coefficient of 13,600 M-1·cm-1 at 412 nm.

Assay of Thioredoxin Activity

The ability of Grx2 to serve as a substrate of thioredoxin reductase was determined in the reduction of 5,5'-dithiobis(2-nitrobenzoic acid). This was followed at 412 nm in 100 mM Tris-Cl, pH 8.0, 2 mM EDTA, 0.1 mg/ml bovine serum albumin, 0.2 mM NADPH, 35 nM E. coli thioredoxin reductase, and 0.5 mM 5,5'-dithiobis(2-nitrobenzoic acid) as described (12). E. coli thioredoxin was used as a positive control.

Insulin Reduction by GSH

Measurements were done at 340 nm using the HED assay for glutaredoxin (100 mM Tris-Cl, pH 8.0, 2 mM EDTA, 0.1 mg/ml bovine serum albumin, 0.2 mM NADPH, 1 mM GSH, 6 µg/ml glutathione reductase) (3) but with bovine insulin (33 µM) in place of HED as a disulfide substrate.

Preparation of Cellular Fractions from E. coli

Periplasmic fractions were prepared after three cycles of quick freezing and thawing in dry ice-ethanol bath, in phosphate-buffered saline at an A600 of 40 (18). The supernatant after centrifugation was collected as the periplasmic lysate fraction. To prepare osmotic shock fractions, cells were initially resuspended (A600 = 40) in ice-cold 20% sucrose, 20 mM Tris-Cl, pH 8.0, with or without 1 mM EDTA for 10 min. They were then resuspended in ice-cold 100 mM Tris-Cl, pH 8.0, 1 mM EDTA and left on ice for 10 min. Cells were finally centrifuged and the supernatant was collected as the osmotic shock fraction (13).

SDS-PAGE

This was performed according to Laemmli (19) using the Bio-Rad mini gel apparatus. Gels were stained with Coomassie Blue.


RESULTS

Cloning of grxB

The sequence for the 18 NH2-terminal residues of Grx2 including its active site was determined previously (6). We now digested Grx2 with either Lys-C endoprotease or Asp-N endoprotease and separated the peptides by HPLC. Altogether 26 peptides were analyzed by automated Edman degradation (Fig. 1). Based on the NH2-terminal sequence and internal peptide K8, primers were designed (N2 and C1) which following PCR resulted in the generation of an 180-bp PCR product containing part of the sequence of grxB. The 180-bp PCR product was used as a probe to screen the Kohara phage library (16) and a positive clone (lambda  233) was identified. After cleavage of lambda  DNA with EcoRI and BamHI a 4.2-kilobase fragment which hybridized with the PCR probe was cloned and sequenced. The novel sequence revealed in the 4.2-kilobase fragment was named grxB region (1943 bp) (Fig. 1) and contained the sequences of grxB and another open reading frame (ORF) upstream grxB.

The 645-bp ORF for grxB encodes a 215-amino acid residue protein with a predicted molecular mass of 24.3 kDa. The deduced amino acid sequence was in agreement with the available amino acid sequence data from the peptides derived from purified Grx2. The NH2-terminal methionine is coded for by GTG. A consensus ribosomal binding site (GGAGG) is located 6 bp upstream of the initiator GTG codon. There are two -35 TTGACa promoter consensus sequences upstream of grxB there but no obvious -10 TAtAaT consensus (Fig. 1).

grxB is partially overlapping with the pyrC region data base entry (Fig. 2) and is located 802 bp upstream from the actual E. coli gene for dihydroorotase (pyrC) (23.4 min) (20). The gene encoding the NH2-terminal acetylase of ribosomal protein S5 (rimJ) (23.7 min) (21) starts 1216 bp upstream from grxB, but is translated from the complementary DNA strand. In fact both grxB and pyrC regions are translated anticlockwise.


Fig. 2. Positioning of the grxB region on the E. coli gene map. The diagram corresponds to the ~4.2-kilobase EcoRI-BamHI fragment in which the grxB region (1943 bp) was found. g20.3, ORF downstream rimJ; rimJ, gene encoding amino-terminal acetylase of ribosomal protein S5; ORFbefgrxB, gene encoding the putative class II transmembrane antiporter before the gene coding for Grx2; grxB, gene encoding Grx2; ORFbefpyrC, ORF before pyrC; pyrC, gene for E. coli dihydroorotase. Unique restriction sites are indicated. Arrows show the 5' to 3' reading frame for grxB and the other genes.
[View Larger Version of this Image (14K GIF file)]


Sequence and Structure of a Novel Putative Membrane Protein

An ORF corresponding to 402 amino acids is located immediately upstream of grxB, before rimJ (Figs. 1 and 2). A GGAGG consensus ribosomal binding site is located three bases upstream from the first Met residue or 12 bp upstream to an alternative GTG-encoded Met. The TMAP program for the prediction of transmembrane proteins (22) aligned the putative protein to well established transmembrane proteins and a membrane orientation model was constructed (Fig. 3). The grxB region containing grxB and the preceding ORF has been submitted to the EMBL data base with accession number X92076[GenBank].


Fig. 3. Membrane orientation model for the protein sequence from ORFbefgrxB. Boxes represent the putative transmembrane domains. Potential alpha -helices are numbered 1-12.
[View Larger Version of this Image (37K GIF file)]


Expression and Purification of Recombinant Grx2

The gene sequence used for the overexpression of Grx2 was identical to the chromosomal one with the exception that the GTG initiator codon was substituted with ATG to increase expression levels since GTG has been reported as a less efficient start codon compared with ATG (23). Using the overexpression system for Trx fusions (13) with Grx2 replacing Trx, recombinant Grx2 was expressed in a soluble state as high as 50% of total cell protein (Fig. 4). Chromatographies on columns of DE52 cellulose and Sephadex G-50 superfine resulted in a homogeneous protein. A yield of 40% from the purification procedure was obtained. A summary of the purification procedure and yields is shown in Table I. The molecular mass of the recombinant Grx2 was determined as 24.3 kDa by matrix-assisted laser desorption/ionization mass spectrometry. This value is identical to that predicted from the genomic sequence. Peptide sequencing showed that the initiation Met was present in preparations of the recombinant enzyme as was also the case for protein isolated from E. coli cells (6). The specific activity of the recombinant Grx2 (316 units/mg, Table I) is identical to the value published before (6) for the wild type enzyme which was based on a Mr of 27,000 rather than the correct value of 24,300. 


Fig. 4. Purification of Grx2. The state of purity of overexpressed Grx2 is shown on a reducing 15% SDS-PAGE gel for a total cell lysate supernatant before the DE52 column (lane 1), after the DE52 column and before gel filtration (lane 2), and after gel filtration on a G-50 superfine column (lane 3, pure Grx2). Lane 4 corresponds to pure Grx1. Preparations of resolubilized truncated mutants corresponding to amino acids 1-114 and 1-133 are shown in lanes 5 and 7, respectively. Lane 6 corresponds to the total cell lysate supernatant of bacteria in which Grx2 1-133 was overexpressed. The amount of protein loaded per lane is 10 µg for the total cell lysate supernatants and 5 µg for the rest.
[View Larger Version of this Image (72K GIF file)]


Table I.

Purification of recombinant Grx2 from 6.2 g of E. coli GI698-pe1Grx2 cells


Step Proteina Volume Activityb Total activity Specific activity Yield

mg ml units/ml units units/mg %
Cell lysate supernatant 695 57 1283 73,133 105 100
DE52 pool (concentrated) 208 3 14,122 42,367 204 58
G50 pool 141 12 2455 29,462  210c 40

a Protein was determined by the method of Bradford (14).
b One unit of activity is 1 µmol of NADPH oxidized per min in the standard HED assay (3).
c The specific activity of purified Grx2 was 316 units/mg using A280 values for Grx2 and a molar extinction coefficient of 21,860 M-1 · cm-1.

Grx2 Activity as a GSH-disulfide Oxidoreductase

Previous results (6) suggested that a large part of the GSH-disulfide oxidoreductase activity in E. coli cells measured by the standard HED assay (Equations 1 and 2) is due to Grx2. To compare the steady-state contribution of HED reducing activities of the three E. coli glutaredoxins, we determined their apparent Km and kcat values for GSH using the standard HED assay which employs final concentrations of 1 mM GSH and 0.7 mM HED. Comparison was also made with human glutaredoxin (hGrx) (24, 25). Due to the spontaneous reaction between HED and GSH leading to increased NADPH consumption, we only determined rates up to 4.5 mM GSH (Fig. 5). The kinetic data (Fig. 5, Table II) showed that Grx2 had the lowest apparent Km for GSH and the highest turnover.


Fig. 5. Comparison of relative activity of Grx1, Grx2, Grx3, and human Grx (hGrx) (24, 25) with GSH in the GSH-disulfide oxidoreductase assay. The conditions of the assay (with 0.7 mM HED) were identical to those previously described (3) with the exception that concentrations of GSH were varied as indicated in the samples containing glutaredoxin and their respective controls. Turnover represents the mole of NADPH oxidized/s by 1 mol of each glutaredoxin. Activity was calculated after subtracting the spontaneous reduction rate observed in the absence of glutaredoxin. Three separate measurements were made for each glutaredoxin and the mean value is shown. Error bars represent 1 S.E.
[View Larger Version of this Image (24K GIF file)]


Table II.

Activity of different glutaredoxins and their properties

The apparent Km (K'm) and apparent turnover values (kcat) were determined for reduction of 0.7 mM HED in the GSH-disulfide oxidoreductase assay (3). Errors shown are ±1 S.E.


Molecular mass Km' kcat

kDa mM S-1
Grx1 9.7 3.0  ± 0.7 115  ± 16
Grx2 24.3 1.8  ± 0.2 554  ± 28
Grx3 9 2.5  ± 0.5 182  ± 20
hGrx 12 1.9  ± 0.2 320  ± 13

Expression and Characterization of Truncated Mutants of Grx2

Sequence alignment of Grx2 with Grx1 and Grx3 showed surprisingly very little homology and identities (Fig. 6). The active site is identical in all three proteins and since Grx2 contains two Cys residues, these must be the catalytic ones located in a similar relative position as in Grx1 and Grx3. Sequence analysis using data base programs revealed some limited homologies to glutathione S-transferases (GSTs) and protein disulfide isomerases (PDIs) (Fig. 6). Since Grx2 seemed to contain Grx-like and PDI-like parts (Fig. 6), we constructed and expressed relevant truncated mutant proteins to examine their possible functional autonomy. The first (amino acids 1-114) mutant corresponded to a part of Grx2 which is long enough to include a Grx-like domain (~80 amino acids). The second mutant was extended to amino acid 133 to include the part with homology to bovine PDI. Both mutants were expressed at high levels but in insoluble states (Fig. 4). Resolubilization from 8 M urea gave 50% pure preparations but no activity could be detected with the standard HED assay for concentrations of the truncated forms up to 10 µM (assuming a 50% purity, data not shown). In comparison, activity of the least active of the four glutaredoxins, Grx1, is detected readily at concentrations of 0.001 µM.


Fig. 6. Sequence alignment of Grx2 and prediction of secondary structure. The alignment of Grx2 with Grx1, Grx3, and E. coli GST (GST Eco) was performed using the on-line software facility of Genome Ecole pour les Etudes et de la Recherche en Informatique et Electronique. The alignment of Grx2 with the different PDI was made using the BLAST program software of the National Center for Biotechnology Information. Secondary structure information was obtained using the secondary structure prediction software of Rost and Sander (29). L, prediction for loop; alpha , prediction for alpha -helix; beta ; prediction for beta -pleated sheet structure. Alignment to GST from Pseudomonas (GST Ps), GST 6.0, and S-crystallin SL11 was performed using the TMAP program (22). Identical amino acids are boxed.
[View Larger Version of this Image (53K GIF file)]


Grx2 as a Reductant of Insulin Disulfides

Trx and Grx1 reduce disulfides in insulin, with Grx1 being a much less efficient enzyme (3). Our results show that Grx2 and Grx3 did not reduce insulin using 1 mM GSH (Fig. 7). This probably reflects an unfavorable enzyme substrate interaction and/or an elevated redox potential for Grx2 and Grx3. The fact that purified Grx2 was obtained in a fully reduced state, as measurements of free SH-groups showed, suggests that Grx2 has a high redox potential and is rather oxidizing.


Fig. 7. GSH-dependent reduction of insulin by glutaredoxins. Insulin, 30 µM, was used in place of 0.7 mM HED in the GSH-disulfide oxidoreductase assay (see "Materials and Methods"). The concentrations of glutaredoxins were varied and activity is expressed as oxidation of NADPH at 340 nm.
[View Larger Version of this Image (15K GIF file)]


Grx2 Is Not a Substrate for Thioredoxin Reductase

Recombinant alkaline phosphatase can be expressed as an active protein with all its correct disulfides in E. coli trxB mutants, but this cannot happen in trxA mutants lacking thioredoxin (26). This suggests the presence of an alternative substrate for thioredoxin reductase which reduces and inactivates alkaline phosphatase (26). Grx2 did not reduce 5,5'-dithiobis(2-nitrobenzoic acid), demonstrating that it was not a substrate for thioredoxin reductase (data not shown). To examine whether GSH was required for thioredoxin reductase-Grx2 interactions, standard HED assays were carried with thioredoxin reductase substituting for glutathione reductase. Grx2 was not reduced under these conditions as measured at 340 nm showing that it did not react with thioredoxin reductase through GSH.

Intracellular Localization of Grx2

To examine the intracellular localization of Grx2, periplasmic and cytosolic fractions of non-transformed E. coli cells and transformants were analyzed by SDS-PAGE (Fig. 8). Grx2 was clearly cytosolic. The enzyme was not released (even when overexpressed) by osmotic shock conditions which is different from Trx (1, 13) and Grx1 (1).


Fig. 8. Preparation of different E. coli cell fractions to localize Grx2. Fractions representing equal cell numbers were loaded on a reducing 10% SDS-PAGE gel. PFCL, cell lysate without periplasmic fraction; PF, periplasmic fraction; SW, supernatant of 20% sucrose wash (osmotic shock); TE, supernatant in 100 mM Tris-Cl, pH 8.0, 1 mM EDTA following sucrose wash; OSCL, cell lysate after osmotic shock without SW and TE fractions; T, supernatant in 100 mM Tris-Cl, pH 8.0 following sucrose wash; TCLS, total cell lysate supernatant; 8M US, insoluble material corresponding to the TCLS, resolubilized in 8 M urea, 100 mM dithiothreitol, pH 8.0, 1 mM EDTA.
[View Larger Version of this Image (71K GIF file)]



DISCUSSION

This paper describes the cloning and sequence determination of a genomic region containing grxB and presents findings on the characterization of recombinant Grx2. Previously two other glutaredoxins from E. coli, both 9-kDa proteins, were shown to have the same active site sequence Cys-Pro-Tyr-Cys and to catalyze GSH-disulfide oxidoreductions via a GSH-binding site (7, 27). Grx2 contains the same active site sequence Cys-Pro-Tyr-Cys as the other two glutaredoxins and is highly active in the general GSH-disulfide oxidoreductase assay with the small disulfide HED as a substrate. Grx2, however, has a larger size and lacks activity as a hydrogen donor (protein disulfide reductase) for ribonucleotide reductase (6). Alignment of Grx2 with other proteins showed no further extensive homology to known glutaredoxins or thioredoxins (Fig. 6). Grx2 therefore lacks the conserved sequences of Grx1 and Grx3 defining a GSH-binding site previously experimentally verified by NMR for the mixed disulfide between E. coli Grx1 C14S and GSH (28). Amino acid residues of Grx2 that may be the homologues to amino acids of Grx1 involved in binding to GSH (underlined) are Y11 (13 in Grx1), QVP49 (P60 in Grx1), and YVD70 (74 in Grx1).

Data base searches showed that Grx2 was weakly homologous to sequences of two GSH S-transferases (GSTs) (Grx2 amino acids 47-69 and 86-112), a relative of GSTsigma , crystallin SL-11 (28) (Grx2 amino acids 16-71), and PDIs of different organisms (70-180) (Fig. 6). The significance of this is unknown. Secondary structure prediction using the method of Rost and Sander (29) suggested that the first third of Grx2 (2-70) contained an alternation of beta -sheets and alpha -helices (beta alpha beta alpha beta beta ), while the remaining part (84-212) was predominantly helical (Fig. 6). The beta alpha beta alpha beta beta prediction for the NH2-terminal third of the molecule is similar to the characteristic beta alpha beta alpha beta beta alpha secondary structure of the thioredoxin fold found in E. coli Trx (10), Grx1 (8), Grx3 (7), glutathione peroxidase (30), and GSH S-transferases (GST) (31). In the latter a first Trx-like domain (~80 amino acids) is connected (through a short linker of 8 amino acids for GSTµ) (32) to a second domain (~130 amino acids) composed of alpha  helices (31). Although the amino acid sequence of Grx2 was markedly different from other members of the Trx superfamily or GSTs including the known E. coli GST (Fig. 6) (33), the NH2-terminal third of the molecule may have the thioredoxin fold. E. coli DsbA, for example, has almost no sequence homology to Trx (34) but contains a Trx-like domain. To examine whether Grx2 contained a fully active Trx/Grx-like domain at its NH2 terminus, we overexpressed two truncated mutant proteins. The first (1-114) included the putative beta alpha beta alpha beta beta alpha fold and the second (1-133) included a part with homology to bovine PDI (Fig. 6). Both overexpressed protein fragments were inactive in the glutaredoxin assay (HED assay). These data suggested that the GSH-disulfide oxidoreductase activity of Grx2 requires parts of the COOH-terminal half of the molecule and is not confined to a Grx1-like NH2-terminal subdomain. In comparison, human PDI contained distinct Trx domains which can be expressed as soluble proteins which catalyze thiol-disulfide exchange reactions (35). Grx2 therefore appears more similar to GSTs in which the GSH-binding site is not confined exclusively to the beta alpha beta alpha beta beta alpha Grx-like first domain but also includes residues from the second domain (alpha 4/alpha 5 helix-turn-helix segment and COOH terminus) (31, 32). Grx2 residues that may be the homologues of GST residues known to interact with GSH (underlined) are Y6 (6 in GSTµ, 7 in GSTpi , and 8 in GSTalpha ) (31), V in QVP49 (QP55 in seven different GSTalpha s) (31), and perhaps the W in WL90 (L47 in eight different GSTµs) (31). Biochemically Grx2 was different from GSTs as it was inactive in the standard 1-chloro-2,4-dinitrobenzene assay for GST activity (36) and did not form the sigma -complex with 1,3,5-trinitrobenzene (37) as GSTs do.2 Furthermore, Grx2 is a monomeric and not a dimeric enzyme either in its reduced or oxidized form as determined by Superdex G-75 chromatography in either 20 or 100 mM potassium phosphate, pH 7.0. In comparison, all known GSTs form homodimeric complexes in solution (31).

The ORF immediately upstream grxB was predicted as a transmembrane protein, using the TMAP program for the prediction and alignment of transmembrane proteins (22). Homologies were observed with other transmembrane transporter proteins and a membrane orientation model was constructed (Fig. 3) after sequence alignment with the metal-tetracycline/H+ antiporter 1 which is thought to contain 12 membrane spanning segments (38). In this model the ORF follows the positive inside rule for transmembrane proteins (39) as it contains one Arg in the periplasm compared with 25 Arg, and Lys in the cytosol. Similarities with other transmembrane proteins reside on the sequence AIAFA between potential alpha 2 and alpha 3 (GXXXD(R/K)XGR(R/K) is the consensus for transmembrane transporters) (40). Transporters which aligned with the ORF include four tetracycline antiporters (TetA, B, C, and D), the quinolone resistance protein from Staphylococcus aureus (NorA) (41), and the multidrug resistance protein from Bacillus subtilis (Bmr) (42). Since these transporters belong to class II of transmembrane proteins (40), we suggest that the ORF before Grx2 also is a member of this class.

The ORF transporter contains 5 Cys residues (Fig. 3), although none with the thioredoxin CXXC active-site motif. Cysteine residues also were present in other transmembrane proteins that aligned with the ORF (not shown). Of particular interest is whether the ORF transporter (63 bp upstream grxB), Grx2, and the protein encoded by the ORF before pyrC (169 bp downstream grxB) are functionally coupled (in principle the transporter could export a product delivered from Grx2) and belong to the same operon. The latter could be possible because although there are two -35 TTGACa promoter consensus sequences upstream from grxB there is no obvious -10 TAtAaT consensus. Also, there is no obvious consensus for the termination of transcription downstream from the ORF before grxB or grxB itself. However, there is a transcriptional terminator downstream from the ORF before pyrC and expression of the pyrC genes is known to be independent from genes upstream (20).

The catalytic activity of recombinant Grx2 and three other classical glutaredoxins was compared in the GSH-disulfide oxidoreductase assay varying the concentrations of GSH with the HED concentration constant (0.7 mM). All the different glutaredoxins had similar apparent Km values for GSH (Fig. 5 and Table II) but Grx2 showed the highest apparent kcat. Grx2 previously was calculated to represent a major part of the total glutaredoxin activity in an E. coli Grx1 null mutant (6). Since the physiological concentrations of GSH in E. coli is from 3.5 to 6.6 mM (43), Grx2 should have the potential of being a major catalyst in GSH-utilizing reactions. The situation may be more complicated. Grx1 has been reported (6) to amount to only 2% of total E. coli oxidoreductase activity (HED assay) (5) but its levels are highly variable and depend on other factors (for example, the levels of ribonucleotide reductase, Trx and GSH) which regulate the intracellular redox environment (44). If Grx2 levels are regulated is unknown and requires further studies.

The biological function of Grx2 is unknown and will require further studies. If Grx2 has a high redox potential it may be involved in GSH-dependent thiol-disulfide exchange reactions making disulfides in proteins. Such reactions and other potential physiological roles linked to the transporter can be addressed by gene inactivation experiments currently in progress.


FOOTNOTES

*   This work was supported by grants from the Wenner-Gren foundation, the Swedish Cancer Society (961 and 1806), the Swedish Medical Research Council (13X-3529, 13X-10832, and 13X-11213), the Karolinska Institute, and the Knut and Alice Wallenberg Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   Present address: Dept. of Bioscience, Karolinska Institute, Novum, 141 57 Huddinge, Sweden.
par    To whom correspondence should be addressed: Medical Nobel Institute for Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden. Tel.: 46-8-7287686; Fax: 46-8-7284716.
1   The abbreviations used are: Grx, glutaredoxin; grxB, gene encoding Grx2; Trx, thioredoxin; HED, beta -hydroxyethyl disulfide; ORF, open reading frame; bp, base pair; PAGE, polyacrylamide gel electrophroesis; HPLC, high performance liquid chromatography; GST, glutathione S-transferase; PDI, protein disulfide isomerase.
2   R. Morgenstern, Karolinska Institute, Department of Toxicology, personal communication.

ACKNOWLEDGEMENTS

We are grateful to Carina Jonsson for excellent technical assistance, Valentina Bonetto for the determination of the molecular mass of recombinant Grx2 by matrix-assisted laser desorption/ionization mass spectrometry, and Dr. Ralf Morgenstern for the TNB and CDNB assays. The generous help of Malin Rohdin is also acknowledged.


REFERENCES

  1. Holmgren, A. (1985) Annu. Rev. Biochem. 54, 237-271 [CrossRef][Medline] [Order article via Infotrieve]
  2. Holmgren, A. (1989) J. Biol. Chem. 264, 13963-13966 [Free Full Text]
  3. Holmgren, A., and Åslund, F. (1995) Methods Enzymol. 252, 283-292 [Medline] [Order article via Infotrieve]
  4. Holmgren, A. (1976) Proc. Natl. Acad. Sci. U. S. A. 73, 2275-2279 [Abstract]
  5. Holmgren, A. (1979) J. Biol. Chem. 254, 3664-3671 [Medline] [Order article via Infotrieve]
  6. Åslund, F., Ehn, B., Miranda-Vizuete, A., Pueyo, C., and Holmgren, A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9813-9817 [Abstract/Free Full Text]
  7. Åslund, F., Nordstrand, K., Berndt, K. D., Nikkola, M., Bergman, T., Ponstingl, H., Jörnvall, H., Otting, G., and Holmgren, A. (1996) J. Biol. Chem. 271, 6736-6745 [Abstract/Free Full Text]
  8. Sodano, P., Xia, T., Bushweller, J. H., Björnberg, O., Holmgren, A., Billeter, M., and Wüthrich, K. (1991) J. Mol. Biol. 221, 1311-1324 [Medline] [Order article via Infotrieve]
  9. Xia, T.-H., Bushweller, J. H., Sodano, P., Billeter, M., Björnberg, O., Holmgren, A., and Wüthrich, K. (1992) Protein Sci. 1, 310-321 [Abstract/Free Full Text]
  10. Holmgren, A., Söderberg, B.-O., Eklund, H., and Brändén, C.-I. (1975) Proc. Natl. Acad. Sci. U. S. A. 72, 2305-2309 [Abstract]
  11. Martin, J. L. (1995) Structure 3, 245-250 [Medline] [Order article via Infotrieve]
  12. Holmgren, A., and Björnstedt, M. (1995) Methods Enzymol. 252, 199-208 [CrossRef][Medline] [Order article via Infotrieve]
  13. LaVallie, E. R., DiBlasio, E. A., Kovacic, S., Grant, K. L., Schendel, P. F., and McCoy, J. M. (1993) Bio/technology 11, 187-193 [Medline] [Order article via Infotrieve]
  14. Bradford, M. M. (1976) Anal. Biochem. 141, 515-522
  15. Bergman, T., and Jörnvall, H. (1987) Eur. J. Biochem. 169, 9-12 [Abstract]
  16. Kohara, Y., Akiyama, K., and Isono, K. (1987) Cell 50, 495-508 [Medline] [Order article via Infotrieve]
  17. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1987) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  18. Collet, T. A., Roben, P., O'Kennedy, R., Barbas, C. F., III, Burton, D. R., and Lerner, R. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10026-10030 [Abstract]
  19. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  20. Bäckström, D., Sjöberg, R.-M., and Lundberg, L. G. (1986) Eur. J. Biochem. 160, 77-82 [Abstract]
  21. White-Ziegler, C. A., and Low, D. A. (1992) J. Bacteriol. 174, 7003-7012 [Abstract]
  22. Persson, B., and Argos, P. (1994) J. Mol. Biol. 237, 182-192 [CrossRef][Medline] [Order article via Infotrieve]
  23. Alldread, R. M., Nicholls, D. J., Sundaram, T. K., Scawen, M. D., and Atkinson, T. (1992) Gene 114, 139-143 [Medline] [Order article via Infotrieve]
  24. Padilla, C. A., Martinez-Galisteo, E., Bárcena, T., Spyrou, G., and Holmgren, A. (1995) Eur. J. Biochem. 227, 27-34 [Abstract]
  25. Padilla, C. A., Spyrou, G., and Holmgren, A. (1996) FEBS Lett. 378, 69-73 [CrossRef][Medline] [Order article via Infotrieve]
  26. Derman, A. I., Prinz, W. A., Belin, D., and Beckwith, J. (1993) Science 262, 1744-1747 [Medline] [Order article via Infotrieve]
  27. Bushweller, J. N., Billeter, M., Holmgren, A., and Wüthrich, K. (1994) J. Mol. Biol. 235, 1585-1597 [CrossRef][Medline] [Order article via Infotrieve]
  28. Ji, X., von Rosenvinge, E. C., Johnson, W. W., Tomarev, S. I., Piatigorsky, J., Armstrong, R. N., and Gilliland, G. L. (1995) Biochemistry 34, 5317-5328 [Medline] [Order article via Infotrieve]
  29. Rost, B., and Sander, C. (1993) J. Mol. Biol. 232, 584-599 [CrossRef][Medline] [Order article via Infotrieve]
  30. Ladenstein, R., Epp, O., Bartels, K., Jones, A., Huber, R., and Wendel, A. (1979) J. Mol. Biol. 134, 199-218 [Medline] [Order article via Infotrieve]
  31. Dirr, H., Reinemer, P., and Huber, R. (1994) Eur. J. Biochem. 220, 645-661 [Abstract]
  32. Ji, X., Zhang, P., Armstrong, R. N., and Gilliland, G. L. (1992) Biochemistry 31, 10169-10184 [Medline] [Order article via Infotrieve]
  33. Nishida, M., Kong, K.-H., Inoue, H., and Takahashi, K. (1994) J. Biol. Chem. 269, 32536-32541 [Abstract/Free Full Text]
  34. Martin, J. L., Bardwell, J. C. A., and Kuriyan, J. (1993) Nature 365, 464-468 [CrossRef][Medline] [Order article via Infotrieve]
  35. Darby, N. J., and Creighton, T. E. (1995) Biochemistry 34, 11725-11735 [Medline] [Order article via Infotrieve]
  36. Chen, W.-J., Graminski, G. F., and Armstrong, R. N. (1988) Biochemistry 27, 647-654 [Medline] [Order article via Infotrieve]
  37. Graminski, G. F., Zhang, P., Sesay, M. A., Ammon, H. L., and Armstrong, R. N. (1989) Biochemistry 28, 6252-6258 [Medline] [Order article via Infotrieve]
  38. Yamaguchi, A., Someya, Y., and Sawai, T. (1992) J. Biol. Chem. 267, 19155-19162 [Abstract/Free Full Text]
  39. von Heijne, G. (1992) J. Mol. Biol. 225, 487-494 [Medline] [Order article via Infotrieve]
  40. Griffith, J. K., Baker, M. E., Rouch, A. D., Page, M. G. P., Skurray, R. A., Paulsen, I. T., Chater, K. F., Baldwin, A., and Henderson, P. J. F. (1992) Curr. Opin. Cell Biol. 4, 684-695 [Medline] [Order article via Infotrieve]
  41. Yoshida, H., Bugaki, M., Nakamura, K., Ubukata, K., and Konno, M. (1990) J. Bacteriol. 17, 6942-6949
  42. Neyfakh, A. (1992) Antimicrob. Agents Chemother. 36, 484-485 [Abstract]
  43. Apontoweil, P., and Berends, M. (1975) Biochim. Biophys. Acta 399, 1-9 [Medline] [Order article via Infotrieve]
  44. Miranda-Vizuete, A., Rodriguez-Ariza, A., Toribio, F., Holmgren, A., López-Barea, J., and Pueyo, C. (1996) J. Biol. Chem. 271, 19099-19103 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.